Press Releases

New study data supports the use of Caldolor® in controlling pain and reducing opioid use in surgical patients

        New Vaprisol Study Supports A Reduced Dose In Patients With Severe Liver Impairment  

- Caldolor&#174; launched for use in children<br>- National promotion of Ethyol&#174; initiated<br>- Two new development programs added

NASHVILLE, Tenn. , Feb. 28, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2016 financial results after the market closes on Tuesday, March 7, 2017 .  A conference call and live Internet webcast will be held on

Caldolor reduces fever in pediatric patients with a favorable safety profile

NASHVILLE, Tenn. , Jan. 30, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced that on January 26, 2017 , the U.S. Court of Appeals for the Federal Circuit ruled in favor of

NASHVILLE, Tenn. , Jan. 16, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. ( NASDAQ : CPIX) is pleased to announce the addition of Kenneth J. Krogulski , CFA to its Board of Directors. He is the President and Chief Executive Officer of Berkshire Asset Management LLC .

NASHVILLE, Tenn. , Jan. 9, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. ( NASDAQ : CPIX) , a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, ' Clinigen ') , the global pharmaceutical and services company, announce an exclusive agreement to commercialize the

Cumberland Emerging Technologies Appoints New Senior Executive